異位性皮膚炎藥物市場規模、佔有率、成長分析，按產品類型、藥物類別、治療方法、給藥途徑、分佈和地區分類 - 產業預測，2025-2032 年

預計2023年全球異位性皮膚炎藥物市場規模將達到149.1億美元，將從2024年的162.8億美元成長到2032年的329.2億美元，預測期內（2025-2032年）的複合年成長率為9.2%。

截至 2023 年 10 月，市場洞察顯示企業越來越需要適應快速變化的消費者偏好和技術進步。資料顯示，消費者越來越傾向於永續實踐，越來越喜歡重視環境責任的品牌。此外，隨著企業利用人工智慧和資料分析的進步來改善客戶體驗，數位轉型仍然是關注的重點。對個人化產品和服務的需求日益成長，凸顯了透過資料主導策略了解客戶行為的重要性。競爭格局分析表明，那些重視靈活性和對市場趨勢的應對力的創新公司將有利於成長，而那些適應較慢的公司可能會面臨維持市場佔有率的挑戰。整體而言，敏捷性和永續性是塑造當前市場的關鍵主題。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管分析

異位性皮膚炎治療市場規模（依產品類型）

• 市場概況
• 生技藥品
• 其他

異位性皮膚炎治療市場規模（依藥物類別）

• 市場概況
• 皮質類固醇
• Calcineurin抑制劑
• PDE4 抑制劑
• 生技藥品
• 其他

異位性皮膚炎治療市場規模（依治療方法）

• 市場概況
• 光療
• 定向治療

異位性皮膚炎治療市場規模（依給藥途徑）

• 市場概況
• 局部的
• 腸外
• 口服

異位性皮膚炎治療市場規模分佈

• 市場概況
• 醫院藥房
• 零售藥局
• 其他藥局

異位性皮膚炎治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Novartis AG（Switzerland）
• Pfizer Inc.（USA）
• Astellas Pharma Inc.（Japan）
• Bayer AG（Germany）
• Allergan plc（Ireland）
• Regeneron Pharmaceuticals, Inc.（USA）
• Sanofi SA（France）
• Incyte Corporation（USA）
• AbbVie Inc.（USA）
• Galderma SA（Switzerland）
• Leo Pharma A/S（Denmark）
• Eli Lilly and Company（USA）
• Amgen Inc.（USA）
• GlaxoSmithKline plc（UK）
• Johnson & Johnson（USA）
• Merck & Co., Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Bristol-Myers Squibb Company（USA）
• Almirall, SA（Spain）
• Sun Pharmaceutical Industries Ltd.（India）

結論和建議

Global Atopic Dermatitis Drugs Market size was valued at USD 14.91 billion in 2023 and is poised to grow from USD 16.28 billion in 2024 to USD 32.92 billion by 2032, growing at a CAGR of 9.2% during the forecast period (2025-2032).

As of October 2023, market insights indicate a growing need for businesses to adapt to rapidly evolving consumer preferences and technological advancements. The data reveals a significant shift towards sustainable practices, with consumers increasingly favoring brands that prioritize environmental responsibility. Additionally, digital transformation remains a critical focus, as companies leverage advancements in artificial intelligence and data analytics to enhance customer experiences. The demand for personalized products and services is rising, emphasizing the importance of understanding customer behavior through data-driven strategies. Competitive landscape analysis suggests that innovative companies that prioritize flexibility and responsiveness to market trends are well-positioned for growth, while those lagging in adaptation may face challenges in retaining market share. Overall, agility and sustainability are key themes shaping the current marketplace.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Atopic Dermatitis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Atopic Dermatitis Drugs Market Segments Analysis

Global Atopic Dermatitis Drugs Market is segmented by Product Type, Drug Class, Therapy, Route of Administration, Distribution and region. Based on Product Type, the market is segmented into Biologics and Others. Based on Drug Class, the market is segmented into Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics and Others. Based on Therapy, the market is segmented into Photo Therapy and Directed Therapy. Based on Route of Administration, the market is segmented into Topical, Parenteral and Oral. Based on Distribution, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Other Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Atopic Dermatitis Drugs Market

The global market for atopic dermatitis drugs is anticipated to expand significantly due to the increasing incidence of this condition, which is attributed to factors such as environmental changes, urbanization, and genetic factors. As awareness of atopic dermatitis grows and its prevalence rises, particularly among children and young adults, the demand for effective treatments is expected to surge. This shift in demographics and the associated rise in cases highlight the urgent need for innovative drugs and therapies, driving market growth and development in the global healthcare landscape devoted to managing atopic dermatitis.

Restraints in the Global Atopic Dermatitis Drugs Market

The Global Atopic Dermatitis Drugs market faces significant challenges due to the side effects associated with certain treatments, raising concerns about long-term patient safety. Specifically, systemic immunosuppressants used for managing atopic dermatitis can lead to adverse effects, including increased susceptibility to infections and liver toxicity. These complications not only diminish patients' quality of life but also hinder the overall growth potential of the atopic dermatitis drugs market. As patients and healthcare providers weigh the risks versus benefits of these medications, the concerns surrounding safety could limit their widespread adoption and dampen market expansion.

Market Trends of the Global Atopic Dermatitis Drugs Market

The Global Atopic Dermatitis Drugs market is poised for significant growth through 2031, driven largely by the increasing adoption of JAK inhibitors such as upadacitinib and abrocitinib. These innovative therapies offer rapid symptom relief and effectively address the unmet medical needs of patients suffering from atopic dermatitis, positioning themselves as essential treatment options. Pharmaceutical companies are anticipated to prioritize the development and marketing of JAK inhibitors, capitalizing on their efficacy and favorable safety profiles. As awareness of these therapies expands, they are expected to dominate the treatment landscape, shaping the future of the atopic dermatitis market and enhancing patient outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Atopic Dermatitis Drugs Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Biologics
• Others

Global Atopic Dermatitis Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Corticosteroids
• Calcineurin Inhibitors
• PDE4 Inhibitors
• Biologics
• Others

Global Atopic Dermatitis Drugs Market Size by Therapy & CAGR (2025-2032)

• Market Overview
• Photo Therapy
• Directed Therapy

Global Atopic Dermatitis Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Topical
• Parenteral
• Oral

Global Atopic Dermatitis Drugs Market Size by Distribution & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Other Pharmacies

Global Atopic Dermatitis Drugs Market Size & CAGR (2025-2032)

• North America (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • US
  • Canada
• Europe (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Drug Class, Therapy, Route of Administration, Distribution)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma S.A. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leo Pharma A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almirall, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations